Key Takeaways
- Revenue up 26%, but guidance cut: H1 FY27 consolidated revenue grew 26.4% YoY to ₹113.9 crores, yet the full-year revenue target was lowered from ₹300 crores to a 5–10% downside, as the hospital strategy was pulled forward to prioritize margins over topline.
- Hospitals arrive early, hit breakeven fast: The first 30-bed Ayurveda hospital reached operating breakeven in September 2026, validating a new compact-unit model that management now plans to scale aggressively with five more hospitals this quarter.
- Margin story strengthens despite lower revenue: EBITDA margin improved 180 bps to 12.7%, and FY27 PAT margin guidance of 11–12% was maintained, though management noted it could see a 1% hampering due to hospital depreciation, with anything above 10% being a great platform for next year.
- US launch imminent, spend cautious: Product lineup, warehousing, and Amazon/TikTok accounts are ready; revenue is expected from November onwards, though initial investment is tempered by a strict ROI focus.
- What to watch next quarter: Whether the five new hospitals open on time and replicate the Paschim Vihar unit’s rapid breakeven, the pace of US revenue ramp, and any update on the Jeena Sikho integration framework ahead of the South India entry.
The Hospital Acceleration
- Strategy pulled forward: Hospital entry was originally planned for 2028, but management brought it forward to FY27, citing market conditions, a demand gap, and existing customers asking for it; the explicit goal was to improve company-level margins.
- First unit validates the model: The 30-bed Paschim Vihar hospital in Delhi reached operating breakeven in September 2026, with monthly revenue ramping from ₹5–6 lakhs to ₹22 lakhs, achieved entirely through day therapies and OPD, not inpatient bed occupancy.
- Compact is the new template: Management realized that smaller 10-to-30-bed units reach breakeven faster and deliver better profitability than larger hospitals, so the rollout pipeline now follows this capital-efficient design.
- Pipeline density: Gurgaon hospital opens around Diwali (within 10 days of Oct 26, 2026); Dehradun and Amritsar hospitals are under construction with interiors ongoing; Jaipur and Lucknow hospitals expected to close within 15 days.
- Unit economics ambition: New hospitals are targeted to break even within 60 to 90 days and cross 25–30% PAT within a year of breakeven, though management declined to provide a revenue-per-bed benchmark, calling industry norms “pretty naive” given the day-therapy model.
- South India deferred: Tamil Nadu and Visakhapatnam plans were logically postponed to Q4 FY27 to first build operational understanding from North India units close to the corporate office; the Jeena Sikho collaboration framework will be framed when South hospitals start.
Manprit Singh Chadha: “I don't want to radically change the industry, but when we say that revenue per bed, I really fail to understand that why are we always talking in a hospital about a bed revenue? ... We did it with all the day therapies, the day OPD. So, revenue per bed, if I talk about the industry benchmark, it's claimed INR10,000. I would say why INR10,000?”
Revenue Guidance Reset
- Topline target lowered: FY27 revenue guidance was revised down from ₹300 crores to a 5–10% downside, with management acknowledging “not 5% or so, yes, it could be,” while maintaining 30–35% YoY growth as the target.
- The tradeoff is deliberate: Management framed the lower revenue as a conscious choice: hospitals were brought forward to improve margins, so the guidance cut comes with a rider of better profitability, not operational weakness.
- FY28 conviction intact: The ₹500 crore FY28 revenue target was reaffirmed with “more than confident” language, now expecting ₹150–200 crores from hospitals and the rest from the product business, with profitability “far better than what was earlier discussed,” though management noted they will have to see how other hospitals perform.
- PAT margin held steady: FY27 PAT margin guidance of 11–12% was maintained despite the revenue cut, with H2 needing 13–14% PAT to achieve it; management says this is doable via higher US ticket sizes and forex gains, though hospital depreciation may create a ~1% headwind, and even maintaining above 10% would be a great platform for next year.
- FY28 margin upgrade: PAT margin target for FY28 was raised to 17–18% (from an earlier 14–15%) on the ₹500 crore base, driven by the hospital business contribution.
Manprit Singh Chadha: “Yes, I am lowering, if you take it that way, I am lowering my guidance with a rider that hospitals were brought in because we thought that margins should improve as such for a company. When I'm lowering my guidance, I'm improving the margins.”
Product Business & Core Growth
- Ayurveda products remain the foundation: H1 growth was driven by the core product business, with men’s wellness growing fastest in both ticket size and margins, and the de-addiction product also catching up quickly as a pillar since inception.
- Fertility dominance: Approximately 60% of revenue currently comes from the fertility business, and the company is working on a complete fertility module to deepen this vertical.
- Umbrella branding underway: Sat Kartar is being integrated as an umbrella brand across all packaging and customer touchpoints, signaling a unified brand architecture push.
- Brand ambassador strategy dropped: Big brand ambassadors are no longer part of the plan, though influencers remain in the marketing mix.
- Marketing spend steady: Marketing spend is maintained at 40% of revenue in the product vertical, though the overall company ratio will decline as hospital revenue scales and AI-driven efficiencies kick in.
US & International Expansion
- US launch is operationally ready: Product lineup, warehousing, TikTok accounts, Amazon accounts, and influencer tie-ups are all in place; revenue is expected to start flowing from November onwards.
- Spend discipline: Management is being cautious on initial US investment, emphasizing an ROI-focused approach rather than a land-grab spend.
- UAE next in line: Work has started in Dubai, with product approvals underway; the UAE is the next export market after the US.
- Europe on hold: European expansion has been reconsidered and paused due to the geo-economic situation.
- Measured approach: International expansion is described as measured, compliant, and commercially sustainable, with no rush to scale before proof points are established.
Partnerships & Operational Updates
- Jeena Sikho integration progressing: The MOU is in process, with the team getting trained on Jeena Sikho platforms, though full-fledged operations have not yet started; a new collaboration is also being worked on to launch certain products together.
- Revenue contribution timeline: Jeena Sikho revenue could begin in the later part of Q3 FY27, with the actual collaboration framework for South India to be framed when those hospitals start in Q4.
- GST liquidity unlock: The 57th GST Council allowed input differential as a refund, meaning previously stuck amounts sitting as current assets on the balance sheet become liquid from 1st November, with month-on-month refunds expected thereafter.
- AI development in-house: AI-driven interactions currently account for less than 1% of conversions; scaling AI externally incurred high token costs, so the company shifted to in-house development, which is taking time but is a major ongoing project.
- Capital allocation priorities: Hospitals are the top priority, followed by the US; no plans to enhance factory capex; marketing spend maintained at 40% in the product vertical.
Bed Rollout & Capacity Build
- FY27 bed target on track: 300 beds targeted for FY27, all under the Sat Kartar brand with no Jeena Sikho hospitals planned this fiscal year; 200 beds are achievable soon from Paschim Vihar, Gurgaon, Dehradun, Amritsar, Jaipur, and Lucknow, with work on an additional 100 beds by the beginning of next quarter.
- FY28 bed ambition: 1,000 beds targeted, which will include the Jeena Sikho collaboration when entering the South market.
- Gurgaon concentration: Two hospitals are planned in Gurgaon, with the first opening around Diwali.
Manprit Singh Chadha: “Yes, we are still on track for that, and we are more than confident on that than earlier because with this hospital business starting and, in fact, the first hospital being breakeven and next five hospitals coming in this quarter itself, that INR500 crores in FY28 is still very much intact with a far better profitability than what was earlier discussed.”
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 30–35% YoY, with 5–10% downside to earlier ₹300 cr target | FY27 full year |
| PAT margin | 11–12%, with ~1% headwind possible from hospital depreciation | FY27 full year |
| FY28 revenue | ₹500 crores, with ₹150–200 cr from hospitals | FY28 |
| FY28 PAT margin | 17–18% (raised from earlier 14–15%) | FY28 |
| Hospital openings | Five more hospitals in Q3 FY27; Gurgaon around Diwali | Q3 FY27 |
| Hospital beds | 300 beds (all Sat Kartar); 200 achievable soon, 100 more by next quarter start | FY27 |
| Hospital beds | 1,000 beds, including Jeena Sikho collaboration in South India | FY28 |
| New hospital breakeven | 60–90 days from opening | Per-unit target |
| Hospital unit PAT | 25–30% within a year of breakeven | Per-unit target |
| US revenue start | Revenue flow from November onwards | November 2026 |
| Jeena Sikho revenue | Contribution could begin in later part of Q3 FY27 | Q3 FY27 |
| South India hospitals | Start in last quarter of FY27; Jeena Sikho framework framed then | Q4 FY27 |
| GST refunds | Month-on-month liquidity from 1st November | Effective 1 Nov 2026 |
Key Metrics
| Metric | H1 FY27 |
|---|---|
| Consolidated revenue from operations | ₹113.9 cr, +26.4% YoY |
| EBITDA | ₹14.5 cr, +47.7% YoY |
| EBITDA margin | 12.7%, improved 180 bps YoY |
| Profit after tax | ₹9.25 cr, +26.7% YoY |
| PAT margin | ~8% |
| Revenue growth outlook | 30% to 35% YoY, subject to business conditions |
| FY27 revenue guidance | ₹300 cr with a downside of around 5% to 10% |
| FY28 revenue guidance | ₹500 cr, intact with better profitability than earlier discussed |
| FY28 revenue bifurcation | ₹150 cr to ₹200 cr from hospitals, rest from product business |
| FY27 PAT margin target | 11% to 12% |
| FY28 PAT margin target | 17% to 18%, revised from 14% to 15% |
| Hospital monthly revenue (September 2026) | ₹22 lakhs, ramped from ₹5–6 lakhs |
| H1 hospital revenue contribution | ~₹55 lakhs |
| FY27 bed target | 300 beds, on track, all Sat Kartar Life |
| FY28 bed target | 1,000 beds, includes Jeena Sikho collaboration in South |
| Hospital unit size strategy | 10 to 30 beds per unit |
| Hospital unit breakeven target | 60 to 90 days |
| Hospital unit PAT target after one year | 25% to 30% |
| Repeat customer revenue share | 23.5% |
| Revenue per advisor per day target | ₹7,000 to ₹8,000 |
| Total advisor force | 1,600, 60% employees, 40% freelance |
| Fertility business share of revenue | 60% |
| Marketing spend in product vertical | 40% of revenue |
| AI-driven customer interactions | Not more than 1% |
| H1 PlantoMed revenue | ₹6 cr to ₹7 cr |
| GTA GST refund | From 1st November, previously stuck amounts become liquid cash |